• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌初次手术的术后并发症及其对化疗延迟的影响。

Postoperative Complications of Upfront Ovarian Cancer Surgery and Their Effects on Chemotherapy Delay.

机构信息

Department of Obstetrics and Gynecology, Kuopio University Hospital, 70210 Kuopio, Finland.

Department of Obstetrics and Gynecology, Central Finland's Hospital Nova, 40620 Jyväskylä, Finland.

出版信息

Curr Oncol. 2024 Sep 19;31(9):5630-5642. doi: 10.3390/curroncol31090417.

DOI:10.3390/curroncol31090417
PMID:39330045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11430809/
Abstract

BACKGROUND

Extensive surgery on advanced-stage epithelial ovarian cancer is associated with increased postoperative morbidity, which may cause a delay in or omission of chemotherapy. We examined postoperative complications and their effects on adjuvant treatment in patients undergoing primary debulking surgery (PDS).

METHODS

Stage IIIC-IV epithelial ovarian cancer patients who underwent PDS between January 2013 and December 2020 were included. Patients were divided into two groups according to the radicality of the operation, i.e., extensive or standard surgery, and their outcomes were compared.

RESULTS

In total, 172 patients were included; 119 underwent extensive surgery, and 53 had standard surgery. Clavien-Dindo grade 3-5 (CDC 3+) complications were detected in 41.2% of patients after extensive operations and in 17% after standard surgery ( = 0.002). The most common CDC 3+ complication was pleural effusion. Despite the difference in the complication rates, the delay in chemotherapy did not differ between the extensive and standard groups ( = 0.98).

CONCLUSIONS

Complications are common after PDS. Extensive surgery increases the complication rate, but most complications can be treated effectively; therefore, a delay in adjuvant treatment is rare.

摘要

背景

晚期上皮性卵巢癌的广泛手术与术后高发病率相关,这可能导致化疗的延迟或遗漏。我们研究了行初次肿瘤细胞减灭术(PDS)患者的术后并发症及其对辅助治疗的影响。

方法

纳入 2013 年 1 月至 2020 年 12 月期间行 PDS 的 IIIC-IV 期上皮性卵巢癌患者。根据手术的彻底性将患者分为广泛手术组和标准手术组,比较两组患者的结局。

结果

共纳入 172 例患者;119 例行广泛手术,53 例行标准手术。广泛手术组术后 41.2%的患者发生 Clavien-Dindo 分级 3-5 级(CDC3+)并发症,标准手术组为 17%( = 0.002)。最常见的 CDC3+并发症是胸腔积液。尽管并发症发生率存在差异,但广泛手术组和标准手术组的化疗延迟无差异( = 0.98)。

结论

PDS 后并发症常见。广泛手术会增加并发症发生率,但大多数并发症可以有效治疗,因此辅助治疗的延迟很少见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77e1/11430809/ba1a00cb9630/curroncol-31-00417-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77e1/11430809/4fadebce29a7/curroncol-31-00417-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77e1/11430809/ba1a00cb9630/curroncol-31-00417-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77e1/11430809/4fadebce29a7/curroncol-31-00417-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77e1/11430809/ba1a00cb9630/curroncol-31-00417-g002.jpg

相似文献

1
Postoperative Complications of Upfront Ovarian Cancer Surgery and Their Effects on Chemotherapy Delay.卵巢癌初次手术的术后并发症及其对化疗延迟的影响。
Curr Oncol. 2024 Sep 19;31(9):5630-5642. doi: 10.3390/curroncol31090417.
2
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.新辅助化疗在手术前与手术后化疗用于晚期卵巢上皮癌的初始治疗。
Cochrane Database Syst Rev. 2021 Jul 30;7(7):CD005343. doi: 10.1002/14651858.CD005343.pub6.
3
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.晚期卵巢上皮癌初始治疗中化疗与手术的比较
Cochrane Database Syst Rev. 2021 Feb 5;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub5.
4
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.比较原发性手术与新辅助化疗治疗高肿瘤负荷晚期上皮性卵巢癌的III期随机临床试验(SCORPION试验):围手术期结局的最终分析
Eur J Cancer. 2016 May;59:22-33. doi: 10.1016/j.ejca.2016.01.017. Epub 2016 Mar 19.
5
Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).荷兰妇科肿瘤学审计(DGOA)登记的原发性和间隔细胞减灭术治疗晚期卵巢癌的术后结果。
Gynecol Oncol. 2021 Aug;162(2):331-338. doi: 10.1016/j.ygyno.2021.05.030. Epub 2021 Jun 17.
6
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.前瞻性手术与新辅助化疗后间隔减瘤手术治疗 IIIC 期和 IV 期卵巢癌患者的研究,SGOG SUNNY(SOC-2)试验方案。
J Gynecol Oncol. 2020 Sep;31(5):e86. doi: 10.3802/jgo.2020.31.e86.
7
Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.预测因素分析:行初次肿瘤细胞减灭术或间隔肿瘤细胞减灭术的晚期卵巢癌患者的手术并发症和辅助化疗延迟。
Int J Gynecol Cancer. 2018 Oct;28(8):1520-1528. doi: 10.1097/IGC.0000000000001325.
8
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.在晚期上皮性卵巢癌中,初次肿瘤细胞减灭术时的微小残留病灶与间隔性肿瘤细胞减灭术时的完全肿瘤切除相比:一项生存分析。
Gynecol Oncol. 2020 Apr;157(1):209-213. doi: 10.1016/j.ygyno.2020.01.010. Epub 2020 Jan 15.
9
Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.采用基于证据的分诊算法降低高级别上皮性卵巢癌初次肿瘤细胞减灭术后 90 天死亡率。
Gynecol Oncol. 2019 Oct;155(1):58-62. doi: 10.1016/j.ygyno.2019.08.004. Epub 2019 Aug 8.
10
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.主要术后并发症对卵巢癌细胞减灭术后复发和长期生存的影响。
Gynecol Oncol. 2022 Jul;166(1):8-17. doi: 10.1016/j.ygyno.2022.05.002. Epub 2022 May 12.

引用本文的文献

1
Perioperative Risk Prediction in Major Gynaecological Oncology Surgery: A National Diagnostic Survey of UK Clinical Practice.妇科肿瘤大手术围手术期风险预测:英国临床实践的全国性诊断调查
Diagnostics (Basel). 2025 Jul 6;15(13):1723. doi: 10.3390/diagnostics15131723.
2
Enhancing Prognosis in Advanced Ovarian Cancer: Primary Cytoreductive Surgery and Adjuvant Chemotherapy or Neoadjuvant Chemotherapy and Interval Cytoreduction-A Single-Center Retrospective Observational Study.改善晚期卵巢癌预后:原发性肿瘤细胞减灭术及辅助化疗或新辅助化疗与间歇性肿瘤细胞减灭术——一项单中心回顾性观察研究
Cancers (Basel). 2025 Apr 14;17(8):1314. doi: 10.3390/cancers17081314.
3

本文引用的文献

1
Impact of supradiaphragmatic lymphadenectomy on the survival of patients in stage IVB ovarian cancer with thoracic lymph node metastasis.膈上淋巴结清扫术对伴有胸段淋巴结转移的IVB期卵巢癌患者生存的影响。
Front Oncol. 2023 Aug 10;13:1203127. doi: 10.3389/fonc.2023.1203127. eCollection 2023.
2
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.新诊断及复发的上皮性卵巢癌:ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Oct;34(10):833-848. doi: 10.1016/j.annonc.2023.07.011. Epub 2023 Aug 17.
3
Robotic surgery in ovarian cancer.
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
新诊断晚期卵巢癌的新辅助化疗:美国临床肿瘤学会指南更新
J Clin Oncol. 2025 Mar;43(7):868-891. doi: 10.1200/JCO-24-02589. Epub 2025 Jan 22.
机器人手术在卵巢癌中的应用。
Best Pract Res Clin Obstet Gynaecol. 2023 Aug;90:102391. doi: 10.1016/j.bpobgyn.2023.102391. Epub 2023 Jul 12.
4
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.胸内手术作为晚期卵巢癌初次细胞减灭术的一部分:更上一层楼 - 纪念斯隆凯特琳癌症中心的一项研究。
Gynecol Oncol. 2023 Mar;170:46-53. doi: 10.1016/j.ygyno.2022.12.023. Epub 2023 Jan 6.
5
Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.超根治性手术在晚期上皮性卵巢癌中的应用提高了生存率:来自一家三级转诊中心的结果。
Gynecol Oncol. 2022 Jun;165(3):478-485. doi: 10.1016/j.ygyno.2022.03.023. Epub 2022 Apr 6.
6
Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.在高级妇科卵巢肿瘤的细胞减灭术中进行膈肌切除术的手术结果:一项随机单中心临床试验 - DRAGON。
Gynecol Oncol. 2022 Feb;164(2):271-277. doi: 10.1016/j.ygyno.2021.11.012. Epub 2021 Nov 26.
7
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.欧洲妇科肿瘤学会(ESGO)/国际妇产科超声学会(ISUOG)/国际妇产科联盟肿瘤学组(IOTA)/欧洲妇科内镜学会(ESGE)关于卵巢肿瘤术前诊断的共识声明。
Int J Gynecol Cancer. 2021 Jul;31(7):961-982. doi: 10.1136/ijgc-2021-002565. Epub 2021 Jun 10.
8
Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study).卵巢癌的术前分期:超声、CT与全身扩散加权磁共振成像的比较(ISAAC研究)
Ultrasound Obstet Gynecol. 2022 Feb;59(2):248-262. doi: 10.1002/uog.23654.
9
Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.适当的分诊可进行积极的初次肿瘤细胞减灭术,其发病率和死亡率与化疗后间隔手术相当。
Gynecol Oncol. 2021 Mar;160(3):681-687. doi: 10.1016/j.ygyno.2020.12.026. Epub 2020 Dec 31.
10
Risk Factors for Severe Complications in Ovarian Cancer Surgery.卵巢癌手术严重并发症的危险因素。
In Vivo. 2020 Nov-Dec;34(6):3361-3365. doi: 10.21873/invivo.12174.